Humanized anti-CD19 auristatin antibody-drug conjugates display potent antitumor activity in preclinical models of B-cell malignancies.

被引：0

作者：

Gerber, Hans-Peter ^{[1
]}

Morris-Tilden, Carol ^{[1
]}

Stone, Ivan ^{[1
]}

Jonas, Mechthild ^{[1
]}

Kung-Sutherland, May ^{[1
]}

Miyamoto, Jamie ^{[1
]}

Brown, Lindsay ^{[1
]}

Westendorf, Lori ^{[1
]}

Meyer, Damon ^{[1
]}

Sussman, Django ^{[1
]}

Carter, Paul ^{[1
]}

Law, Che-Leung ^{[1
]}

Grewal, Iqbal S. ^{[1
]}

机构：

[1] Seattle Genetics, Bothell, WA USA

来源：

MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3451S / 3451S

页数：1

共 50 条

[1] Development of novel anti-CD19 antibody-drug conjugates for B-cell lymphoma treatment
Li, Zhuanglin
Wang, Mingxue
Yao, Xuejing
Li, Huanzhao
Li, Shenjun
Liu, Lina
Yu, Deling
Li, Xue
Fang, Jianmin
Huang, Changjiang
INTERNATIONAL IMMUNOPHARMACOLOGY, 2018, 62 : 299 - 308
[2] Potent antitumor activity of the anti-CD19 auristatin antibody-drug conjugate hBU12-vcMMAE in rituximab sensitive and resistant lymphomas
Gerber, H. P.
Stone, I.
Kung-Sutherland, M.
Miyamoto, J.
Okeley, N.
Alley, S. C.
Meyer, D. L.
Sussman, D.
Senter, P.
Grewal, I. S.
EJC SUPPLEMENTS, 2008, 6 (12): : 161 - 161
[3] SGN-CD19B, a Pyrrolobenzodiazepine (PBD)-Based Anti-CD19 Drug Conjugate, Demonstrates Potent Preclinical Activity Against B-Cell Malignancies
Ryan, Maureen C.
Schimpf, Brian
Anderson, Martha
Zeng, Weiping
Emmerton, Kim
Miyamoto, Jamie
Kostner, Heather
Yu, Changpu
Van Epps, Heather
Tatalick, Laurie
Benjamin, Dennis
BLOOD, 2015, 126 (23)
[4] Preclinical evaluation of anti-CD37 antibody-targeted amanitin conjugates (ATAC) in B-cell malignancies.
Voss, Stephanie
Palfi, Aniko
Mueller, Christoph
Pahl, Andreas
Hechler, Torsten
Kulke, Michael
CANCER RESEARCH, 2021, 81 (13)
[5] Preclinical evaluation of a humanized anti-CD74 monoclonal antibody hLL1, for treatment of B-cell malignancies.
Stein, R
Burton, JD
Cardillo, TM
Qu, ZX
Ely, SA
Reddy, P
Chen, S
Rosario, A
Horak, ID
Hansen, HJ
Goldenberg, DM
BLOOD, 2003, 102 (11) : 181A - 181A
[6] Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma
Wu, Lan
Wang, Chong
Zhang, Dapeng
Zhang, Xunming
Qian, Weizhu
Zhao, Lei
Wang, Hao
Li, Bohua
Guo, Yajun
CANCER LETTERS, 2010, 292 (02) : 208 - 214
[7] SGN-35, an anti-CD30 antibody-drug conjugate, exhibits potent antitumor activity for the treatment of CD30+ malignancies.
Hamblett, KJ
Barton, J
Cerveny, CG
Andreyka, JB
Kissler, KM
Okeley, NM
Stone, I
Sutherland, MK
Sun, MM
Senter, PD
Wahl, AF
Ihle, NC
BLOOD, 2005, 106 (11) : 181A - 181A
[8] XmAb®5574, An Fc Engineered Humanized Anti-CD19 Monoclonal Antibody, Has Potent in Vitro and in Vivo Activities, and Has the Potential for Treating B Cell Malignancies.
Lawrence, Chris E.
Zalevsky, Jonathan
Horton, Holly
Leung, Irene
Chu, Seung
Karki, Sher
Zhukovsky, Eugene
Desjarlais, John R.
Carmichael, David F.
BLOOD, 2008, 112 (11) : 907 - 908
[9] Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas
Gerber, Hans-Peter
Kung-Sutherland, May
Stone, Ivan
Morris-Tilden, Carol
Miyamoto, Jamie
McCormick, Renee
Alley, Stephen C.
Okeley, Nicole
Hayes, Brad
Hernandez-Ilizaliturri, Francisco J.
McDonagh, Charlotte F.
Carter, Paul J.
Benjamin, Dennis
Grewal, Iqbal S.
BLOOD, 2009, 113 (18) : 4352 - 4361
[10] Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia
Jain, Nitin
Stock, Wendy
Zeidan, Amer
Atallah, Ehab
McCloskey, James
Heffner, Leonard
Tomlinson, Benjamin
Bhatnagar, Bhavana
Feingold, Jay
Ungar, David
Chao, Grace
Zhang, Xiaoyan
Qin, Yajuan
Havenith, Karin
Kantarjian, Hagop
Wieduwilt, Matthew J.
BLOOD ADVANCES, 2020, 4 (03) : 449 - 457

← 1 2 3 4 5 →